SI2376116T1 - Anti-IGF protitelesa - Google Patents
Anti-IGF protitelesaInfo
- Publication number
- SI2376116T1 SI2376116T1 SI200931372T SI200931372T SI2376116T1 SI 2376116 T1 SI2376116 T1 SI 2376116T1 SI 200931372 T SI200931372 T SI 200931372T SI 200931372 T SI200931372 T SI 200931372T SI 2376116 T1 SI2376116 T1 SI 2376116T1
- Authority
- SI
- Slovenia
- Prior art keywords
- igf antibodies
- igf
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08171554 | 2008-12-12 | ||
EP09771361.4A EP2376116B1 (en) | 2008-12-12 | 2009-12-11 | Anti-igf antibodies |
PCT/EP2009/066894 WO2010066868A2 (en) | 2008-12-12 | 2009-12-11 | Anti-igf antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2376116T1 true SI2376116T1 (sl) | 2016-03-31 |
Family
ID=40512371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200931372T SI2376116T1 (sl) | 2008-12-12 | 2009-12-11 | Anti-IGF protitelesa |
Country Status (39)
Country | Link |
---|---|
US (4) | US8318159B2 (sl) |
EP (2) | EP2376116B1 (sl) |
JP (2) | JP5694184B2 (sl) |
KR (1) | KR101827332B1 (sl) |
CN (3) | CN102227226B (sl) |
AP (1) | AP3371A (sl) |
AR (1) | AR074726A1 (sl) |
AU (1) | AU2009324296B2 (sl) |
BR (1) | BRPI0923359B8 (sl) |
CA (1) | CA2740341C (sl) |
CL (1) | CL2011001431A1 (sl) |
CO (1) | CO6390042A2 (sl) |
CY (1) | CY1117241T1 (sl) |
DK (1) | DK2376116T3 (sl) |
EA (1) | EA029178B1 (sl) |
EC (1) | ECSP11011126A (sl) |
ES (1) | ES2561045T3 (sl) |
GE (1) | GEP20146119B (sl) |
HK (1) | HK1158933A1 (sl) |
HR (1) | HRP20160190T1 (sl) |
HU (1) | HUE026374T2 (sl) |
IL (1) | IL212047A (sl) |
MA (1) | MA32888B1 (sl) |
ME (1) | ME02377B (sl) |
MX (1) | MX2011006055A (sl) |
MY (1) | MY150984A (sl) |
NZ (3) | NZ597692A (sl) |
PE (1) | PE20120415A1 (sl) |
PL (1) | PL2376116T3 (sl) |
PT (1) | PT2376116E (sl) |
RS (1) | RS54423B1 (sl) |
SG (2) | SG172107A1 (sl) |
SI (1) | SI2376116T1 (sl) |
TN (1) | TN2011000299A1 (sl) |
TW (1) | TWI471139B (sl) |
UA (1) | UA105198C2 (sl) |
UY (1) | UY32317A (sl) |
WO (1) | WO2010066868A2 (sl) |
ZA (1) | ZA201102308B (sl) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5535633B2 (ja) * | 2006-09-29 | 2014-07-02 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
PE20090368A1 (es) * | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
EP2190469B1 (en) | 2007-09-04 | 2015-02-25 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US8753632B2 (en) | 2008-11-10 | 2014-06-17 | Novartis Ag | Antibodies to modified human IGF-1/E peptides |
TWI471139B (zh) | 2008-12-12 | 2015-02-01 | Boehringer Ingelheim Int | 抗-igf抗體 |
PT2488204E (pt) | 2009-10-16 | 2016-06-09 | Oncomed Pharm Inc | Combinação terapêutica e utilização de anticorpos antagonistas de dll4 e agentes anti-hipertensivos |
EP2494070A2 (en) * | 2009-10-30 | 2012-09-05 | Bristol-Myers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
EP2640421A4 (en) * | 2010-11-16 | 2014-05-28 | Medimmune Llc | THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES |
WO2012142164A1 (en) * | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
US9428574B2 (en) | 2011-06-30 | 2016-08-30 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
LT2758073T (lt) | 2011-09-23 | 2019-01-10 | Oncomed Pharmaceuticals, Inc. | Vegf/dll4 surišantys agentai ir jų panaudojimas |
US20130122005A1 (en) | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
CN104185681A (zh) | 2012-02-01 | 2014-12-03 | 卡姆普根有限公司 | C1orf32抗体及其用于治疗癌症的用途 |
EP2900328A4 (en) | 2012-09-25 | 2016-05-11 | Biogen Ma Inc | PROCESS FOR USE OF FIXED POLYPEPTIDES |
CN102863530A (zh) * | 2012-09-26 | 2013-01-09 | 李彬 | 一种脂肪细胞分化代谢产物igf-1抗体及包含该抗体的芯片以及应用 |
US20140227252A1 (en) | 2012-10-31 | 2014-08-14 | Oncomed Pharmaceuticals , Inc. | Methods and Monitoring of Treatment with a DLL4 Antagonist |
US20140255413A1 (en) * | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
KR20210094669A (ko) | 2013-04-29 | 2021-07-29 | 에프. 호프만-라 로슈 아게 | 인간 fcrn-결합 변형된 항체 및 사용 방법 |
WO2015056237A2 (en) * | 2013-10-18 | 2015-04-23 | Universität Für Bodenkultur Wien | Purification of proteins |
CA2934313A1 (en) * | 2013-12-19 | 2015-06-25 | Medimmune, Llc | Compositions and methods for treating sarcoma |
BR112016014969A2 (pt) | 2014-01-15 | 2018-01-23 | Hoffmann La Roche | polipeptídeo, formulação farmacêutica e uso de um polipeptídeo |
JP6712226B2 (ja) * | 2014-01-24 | 2020-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | エキセメスタン及びエベロリムスと組み合わせてインスリン様成長因子(igf)受容体アンタゴニストを用いる癌治療 |
JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
MX2017005258A (es) | 2014-10-31 | 2017-07-26 | Oncomed Pharm Inc | Terapia combinada para tratamiento de enfermedad. |
WO2016113572A1 (en) * | 2015-01-16 | 2016-07-21 | The University Of Liverpool | Insulin-like growth factor inhibitor and chemotherapeutic agent for use in cancer therapy |
WO2017035430A2 (en) * | 2015-08-27 | 2017-03-02 | Kolltan Pharmaceuticals, Inc. | Anti-alk antibodies and methods for use thereof |
CN109071644B (zh) | 2015-09-23 | 2023-09-19 | 昂考梅德药品有限公司 | 治疗癌症的方法和组合物 |
US20170088609A1 (en) | 2015-09-28 | 2017-03-30 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
CN105622730B (zh) * | 2016-02-18 | 2020-06-26 | 深圳华尔康生物科技有限公司 | 一种特异性结合igf-1的多肽及其应用 |
CN110167928A (zh) | 2016-12-22 | 2019-08-23 | 勃林格殷格翰国际有限公司 | 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物 |
WO2019063802A1 (en) | 2017-09-29 | 2019-04-04 | Boehringer Ingelheim International Gmbh | ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1 |
KR20200111163A (ko) | 2017-12-21 | 2020-09-28 | 베링거 인겔하임 인터내셔날 게엠베하 | Sos1 억제제로서의 신규 벤질아미노 치환 피리도피리미디논 및 유도체 |
KR102404684B1 (ko) * | 2019-01-15 | 2022-06-07 | 서울대학교산학협력단 | 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물 |
CN116234806A (zh) | 2020-06-02 | 2023-06-06 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物 |
AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
WO2022223033A1 (zh) | 2021-04-23 | 2022-10-27 | 上海领泰生物医药科技有限公司 | Sos1降解剂及其制备方法和应用 |
WO2023099620A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
TW202340208A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
WO2023099592A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
TW202340209A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
WO2023099624A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
TW202337432A (zh) | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
CN114671949B (zh) * | 2022-04-20 | 2023-04-28 | 山西农业大学 | 一种igf1纳米抗体及其应用 |
WO2023225657A2 (en) * | 2022-05-20 | 2023-11-23 | Rezolute, Inc. | Formulations for anti-insulin receptor antibody and uses thereof |
WO2024080509A1 (ko) * | 2022-10-14 | 2024-04-18 | 포항공과대학교 산학협력단 | Igf-1 수용체 결합 압타머 및 이의 용도 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
EP0561137B1 (en) | 1983-04-25 | 2002-07-03 | Chiron Corporation | Hybrid DNA Synthesis of Mature Insulin-like Growth Factors |
WO1985000831A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
AU1232188A (en) | 1987-05-29 | 1988-12-01 | Mallinckrodt, Inc. | Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i |
DE68908175T2 (de) | 1988-05-27 | 1994-03-03 | Centocor Inc | Gefriergetrocknete formulierung für antikörperprodukte. |
WO1990000562A1 (en) | 1988-06-30 | 1990-01-25 | Pierre Demeyts | Insulinomimetic and insulin receptor binding site peptides |
CA2058041A1 (en) | 1990-06-27 | 1991-12-28 | Katsuichi Sakano | Anti-igf-ii monoclonal antibody |
ES2138662T3 (es) | 1993-06-03 | 2000-01-16 | Therapeutic Antibodies Inc | Produccion de fragmentos de anticuerpos. |
WO1995025794A1 (fr) | 1994-03-23 | 1995-09-28 | Japan Clinical Laboratories | Anticorps monoclonal anti-igf-i |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
ATE328903T1 (de) | 1997-11-27 | 2006-06-15 | Commw Scient Ind Res Org | Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462) |
ATE269357T1 (de) | 1999-04-28 | 2004-07-15 | Univ Texas | Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf |
NZ569856A (en) | 2001-01-05 | 2010-03-26 | Pfizer | Antibodies to insulin-like growth factor 1 receptor |
IL156955A0 (en) | 2001-01-17 | 2004-02-08 | Genecraft Inc | Binding domain-immunoglobulin fusion proteins |
JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
CN100410275C (zh) | 2002-01-18 | 2008-08-13 | 皮埃尔法布雷医药公司 | 新的抗igf-ir抗体及其应用 |
US7438911B2 (en) | 2002-04-30 | 2008-10-21 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human insulin-like growth factor |
JP2003310275A (ja) | 2002-04-30 | 2003-11-05 | Kyowa Hakko Kogyo Co Ltd | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
EP1506286B1 (en) | 2002-05-24 | 2014-03-19 | Merck Sharp & Dohme Corp. | Neutralizing human anti-igfr antibody |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
US20030138430A1 (en) * | 2002-09-20 | 2003-07-24 | Stimmel Julie Beth | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
CA2511910A1 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
PL378812A1 (pl) | 2003-02-13 | 2006-05-29 | Pfizer Products Inc. | Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I |
JP2007528201A (ja) | 2003-03-14 | 2007-10-11 | ファルマシア・コーポレーション | 癌治療のためのigf−i受容体に対する抗体 |
ES2527871T3 (es) | 2003-05-01 | 2015-02-02 | Imclone Llc | Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana |
US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
JPWO2005018671A1 (ja) | 2003-08-21 | 2006-10-19 | 協和醗酵工業株式会社 | 癌転移阻害剤 |
US7498415B2 (en) | 2003-09-24 | 2009-03-03 | Kyowa Hakko Kogyo Co., Ltd. | Recombinant antibody against human insulin-like growth factor |
CA2540133A1 (en) | 2003-09-24 | 2005-03-31 | Kyowa Hakko Kogyo Co., Ltd. | Drugs for treating cancer |
WO2005058967A2 (en) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
CN101014365B (zh) | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤 |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
US20090123950A1 (en) | 2005-05-24 | 2009-05-14 | Morphosys Ag | Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38 |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
HUE035250T2 (hu) | 2005-10-12 | 2018-05-02 | Morphosys Ag | Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása |
CA2633956C (en) | 2005-12-13 | 2016-12-06 | Olivia Raeber | Binding proteins specific for insulin-like growth factors and uses thereof |
AP2008004569A0 (en) | 2006-02-03 | 2008-08-31 | Imclone Systems Inc | IGR-IR antagonists as adjuvants for treatment of prostrate cancer |
WO2007126876A2 (en) | 2006-03-28 | 2007-11-08 | Biogen Idec Ma Inc. | Anti-igf-ir antibodies and uses thereof |
BRPI0709481A2 (pt) | 2006-04-07 | 2011-07-19 | Government Of The Us Secretary Dept Of Health And Human Services | anticorpo monoclonal isolado, anticorpo monoclonal humano isolado, composição farmacêutica, anticorpo anti-igf-i e anti-igf-ii recombinante isolado ou fragmento de ligação ao antìgeno do mesmo, método para detectar o fator i e o fator ii de crescimento insulina humana em uma amostra, método para dectetar o fator i de crescimento insulina humana em uma amostra, ácido nucléico isolado, célula recombinante , célula hospedeira ,método para preparar um anticorpo, método para preparar um anticorpo, método para tratar uma doença neoplásica em um indivìduo mamìfero, método para diagnosticar doença neoplásica em um indivìduo mamìfero e método para classificar um composto candidato a fármaco |
US20080014203A1 (en) | 2006-04-11 | 2008-01-17 | Silke Hansen | Antibodies against insulin-like growth factor I receptor and uses thereof |
NZ573187A (en) | 2006-06-02 | 2011-11-25 | Pfizer Prod Inc | Circulating tumor cell assay for predicting efficacy of 1gf-1r antagonist therapy |
WO2008005469A2 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
US7749966B2 (en) | 2006-12-21 | 2010-07-06 | Boston Biomedical Research Institute | Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity |
TW200833711A (en) | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
GB0702888D0 (en) | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
MX2009009379A (es) | 2007-03-02 | 2009-09-14 | Amgen Inc | Metodos y composiciones para tratar enfermedades tumorales. |
WO2008115470A2 (en) | 2007-03-16 | 2008-09-25 | East Carolina University | Hox-gene expression as a biomarker for igf-1r therapeutics |
KR20090113340A (ko) | 2007-03-22 | 2009-10-29 | 임클론 엘엘씨 | 안정한 항체 제제 |
WO2008144345A2 (en) | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
WO2008144720A2 (en) | 2007-05-21 | 2008-11-27 | University Of Washington | Inhibitors of igf-1r signaling for the treatment of respiratory disorders |
WO2008152422A2 (en) | 2007-06-12 | 2008-12-18 | Astrazeneca Ab | Binding proteins specific for insulin-like growth factors and uses thereof-909 |
PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
US20110052667A1 (en) | 2007-06-28 | 2011-03-03 | Sylgen Laboratories, Inc. | Compositions and methods for inhibiting angiogenesis and tumorigenesis |
WO2009005673A1 (en) | 2007-06-28 | 2009-01-08 | Schering Corporation | Anti-igf1r |
CA2694990A1 (en) | 2007-07-31 | 2009-02-05 | Merck Sharp & Dohme Corp. | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
EP2190879A1 (en) | 2007-08-01 | 2010-06-02 | Glaxo Group Limited | Novel antibodies |
WO2009019117A1 (en) | 2007-08-03 | 2009-02-12 | Affibody Ab | Igf-1r binding polypeptides and their use |
WO2009021054A2 (en) | 2007-08-06 | 2009-02-12 | Orion Genomics Llc | Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene |
KR20100052545A (ko) | 2007-08-28 | 2010-05-19 | 바이오겐 아이덱 엠에이 인코포레이티드 | Igf―1r의 다중 에피토프에 결합하는 조성물 |
WO2009032145A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-igf-1r antibodies and uses thereof |
EP2193211A4 (en) | 2007-09-19 | 2010-12-08 | Univ Boston | IDENTIFICATION OF NEW PATHWAYS FOR THE DEVELOPMENT OF MEDICINES FOR THE TREATMENT OF LUNG DISEASES |
CA2694356A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
AU2008307634A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗-vegf抗體 |
EP2247757A2 (en) | 2007-12-18 | 2010-11-10 | Schering Corporation | Biomarkers for sensitivity to anti-igf1r therapy |
US20090258365A1 (en) | 2008-03-25 | 2009-10-15 | Terstappen Leon W M M | METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH |
WO2009126304A1 (en) | 2008-04-11 | 2009-10-15 | Biogen Idec Ma Inc. | Therapeutic combinations of anti-igf-1r antibodies and other compounds |
CA2722992A1 (en) | 2008-05-05 | 2009-11-12 | Schering Corporation | Sequential administration of chemotherapeutic agents for treatment of cancer |
WO2009137758A2 (en) | 2008-05-09 | 2009-11-12 | Dyax Corp. | Igf-ii/gf-iie binding proteins |
BRPI0913366A8 (pt) | 2008-06-03 | 2017-07-11 | Abbott Lab | Imunoglobulinas de domínio variável duplo e seus usos |
JP2012503612A (ja) | 2008-09-26 | 2012-02-09 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異性抗egfr/抗igf−1r抗体 |
JP2012503487A (ja) | 2008-09-26 | 2012-02-09 | シェーリング コーポレイション | 高力価抗体の製造 |
EP2349329A4 (en) | 2008-10-14 | 2012-10-31 | Dyax Corp | USE OF IGF-II / IGF-II BINDING FOR THE TREATMENT AND PREVENTION OF SYSTEMIC SCLEROSIS ASSOCIATED WITH LUNG FIBROSIS |
US8163509B2 (en) | 2008-10-20 | 2012-04-24 | The Regents Of The University Of Colorado, A Body Corporate | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US8753632B2 (en) | 2008-11-10 | 2014-06-17 | Novartis Ag | Antibodies to modified human IGF-1/E peptides |
CN104398471A (zh) | 2008-11-28 | 2015-03-11 | Abbvie公司 | 稳定的抗体组合物和用于稳定其的方法 |
TWI471139B (zh) | 2008-12-12 | 2015-02-01 | Boehringer Ingelheim Int | 抗-igf抗體 |
WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
EP2381774A4 (en) | 2008-12-23 | 2012-07-18 | Salk Inst For Biological Studi | METHOD OF TREATING NEURODEGENERATIVE DISEASE |
BRPI1015216A2 (pt) | 2009-04-16 | 2016-04-12 | Merck Sharp & Dohme | método de tratar ou prevenir uma condição médica em um indivíduo. |
WO2011057064A1 (en) | 2009-11-05 | 2011-05-12 | Brian Long | Igf1r inhibitor based treatment of prostate cancer |
EP2852685A1 (en) | 2012-03-30 | 2015-04-01 | Merck Sharp & Dohme Corp. | Igf1 biomarker for igf1r inhibitor therapy |
WO2013169611A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Compositions and methods for treating breast cancer |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
JP6712226B2 (ja) | 2014-01-24 | 2020-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | エキセメスタン及びエベロリムスと組み合わせてインスリン様成長因子(igf)受容体アンタゴニストを用いる癌治療 |
US20170088609A1 (en) | 2015-09-28 | 2017-03-30 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
-
2009
- 2009-12-11 TW TW98142592A patent/TWI471139B/zh active
- 2009-12-11 NZ NZ597692A patent/NZ597692A/xx unknown
- 2009-12-11 US US12/636,195 patent/US8318159B2/en active Active
- 2009-12-11 JP JP2011540115A patent/JP5694184B2/ja active Active
- 2009-12-11 BR BRPI0923359A patent/BRPI0923359B8/pt active IP Right Grant
- 2009-12-11 SI SI200931372T patent/SI2376116T1/sl unknown
- 2009-12-11 CA CA2740341A patent/CA2740341C/en active Active
- 2009-12-11 GE GEAP200912290A patent/GEP20146119B/en unknown
- 2009-12-11 CN CN200980148017.9A patent/CN102227226B/zh active Active
- 2009-12-11 PE PE2011001209A patent/PE20120415A1/es active IP Right Grant
- 2009-12-11 NZ NZ592151A patent/NZ592151A/xx unknown
- 2009-12-11 AU AU2009324296A patent/AU2009324296B2/en active Active
- 2009-12-11 PL PL09771361T patent/PL2376116T3/pl unknown
- 2009-12-11 ME MEP-2015-211A patent/ME02377B/me unknown
- 2009-12-11 MX MX2011006055A patent/MX2011006055A/es active IP Right Grant
- 2009-12-11 WO PCT/EP2009/066894 patent/WO2010066868A2/en active Application Filing
- 2009-12-11 UY UY0001032317A patent/UY32317A/es not_active Application Discontinuation
- 2009-12-11 SG SG2011042876A patent/SG172107A1/en unknown
- 2009-12-11 HU HUE09771361A patent/HUE026374T2/en unknown
- 2009-12-11 EP EP09771361.4A patent/EP2376116B1/en active Active
- 2009-12-11 CN CN2013103122152A patent/CN103396487A/zh active Pending
- 2009-12-11 RS RS20150877A patent/RS54423B1/en unknown
- 2009-12-11 EA EA201100918A patent/EA029178B1/ru not_active IP Right Cessation
- 2009-12-11 NZ NZ597694A patent/NZ597694A/xx unknown
- 2009-12-11 SG SG2014013841A patent/SG2014013841A/en unknown
- 2009-12-11 ES ES09771361.4T patent/ES2561045T3/es active Active
- 2009-12-11 KR KR1020117012844A patent/KR101827332B1/ko active IP Right Grant
- 2009-12-11 PT PT97713614T patent/PT2376116E/pt unknown
- 2009-12-11 AR ARP090104838A patent/AR074726A1/es active IP Right Grant
- 2009-12-11 DK DK09771361.4T patent/DK2376116T3/en active
- 2009-12-11 MY MYPI20112684 patent/MY150984A/en unknown
- 2009-12-11 UA UAA201108588A patent/UA105198C2/ru unknown
- 2009-12-11 EP EP15197949.9A patent/EP3064219A3/en not_active Withdrawn
- 2009-12-11 CN CN2013103138432A patent/CN103396488A/zh active Pending
- 2009-12-11 AP AP2011005719A patent/AP3371A/xx active
-
2011
- 2011-03-29 ZA ZA2011/02308A patent/ZA201102308B/en unknown
- 2011-03-31 IL IL212047A patent/IL212047A/en active IP Right Grant
- 2011-06-09 MA MA33927A patent/MA32888B1/fr unknown
- 2011-06-10 CO CO11072583A patent/CO6390042A2/es active IP Right Grant
- 2011-06-10 CL CL2011001431A patent/CL2011001431A1/es unknown
- 2011-06-10 TN TN2011000299A patent/TN2011000299A1/fr unknown
- 2011-06-13 EC EC2011011126A patent/ECSP11011126A/es unknown
- 2011-12-09 HK HK11113339.0A patent/HK1158933A1/xx unknown
-
2012
- 2012-10-17 US US13/653,843 patent/US20130230541A1/en not_active Abandoned
-
2014
- 2014-06-13 US US14/304,338 patent/US10179810B2/en active Active
-
2015
- 2015-02-04 JP JP2015019825A patent/JP2015131812A/ja active Pending
-
2016
- 2016-02-23 HR HRP20160190T patent/HRP20160190T1/hr unknown
- 2016-03-01 CY CY20161100179T patent/CY1117241T1/el unknown
-
2018
- 2018-12-05 US US16/210,334 patent/US11299538B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP3371A (en) | Anti-IGF antibodies | |
ZA201005348B (en) | Humanized anti-c5ar antibodies | |
EP3064512C0 (en) | ANTIBODIES AGAINST CLDN6 | |
IL214996A0 (en) | Anti-bcma antibodies | |
EP2331579A4 (en) | MONOCLONAL ANTIBODIES | |
GB0920127D0 (en) | Antibodies | |
ZA201102119B (en) | Improved antibody libraies | |
GB0909906D0 (en) | Antibodies | |
GB0821100D0 (en) | Antibodies | |
EP2427496A4 (en) | ANTI-VEGF-D ANTIBODIES | |
EP2337798A4 (en) | BSA-SPECIFIC ANTIBODIES | |
EP2259795A4 (en) | ANTI-VEGF ANTIBODY | |
EP2483416A4 (en) | MONOCLONAL ANTIBODIES | |
IL236236A (en) | Antibodies to the fam26f polypeptide | |
ZA201006099B (en) | Anti-tyrp1 antibodies | |
GB0920324D0 (en) | Antibodies | |
HK1170745A1 (en) | Antibodies against il-17br il-17br | |
ZA201007976B (en) | Anti-pirb antibodies | |
GB0818356D0 (en) | Antibodies | |
EP2499256A4 (en) | ANTI-C-MPL ANTIBODIES | |
EP2424892A4 (en) | DC-STAMP ANTIBODY | |
GB0911770D0 (en) | Antibody | |
GB0806230D0 (en) | Antibodies | |
GB0823562D0 (en) | Antibodies | |
GB0817621D0 (en) | Antibody |